News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Sharemaestro Market Watch Earnings watch
The Aug. 17 report arrives with the stock flat on the week but still under pressure over the past month.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
ABN AMRO Bank N.V. recently acquired a new position in Quest Diagnostics Incorporated, purchasing 101,667 shares valued at approximately $21.52 million during the second quarter. This investment makes ABN AMRO Bank N.V. an approximate 0.09% owner of the medical research company. Other institutional investors …
This article details Innospec Inc.'s (0JAX) Q1 2024 earnings report, revealing an EPS beat at $1.75 against a consensus of $1.64, while revenue of $500.20M missed expectations slightly. It includes information on the earnings call, slide deck availability, and historical earnings data, alongside estimated …
Wall Street Zen downgraded Cronos Group (NASDAQ:CRON) from a "buy" to a "hold" rating, aligning with the broader analyst consensus of "Hold" and a $2.30 price target. Despite the downgrade, Cronos recently reported strong quarterly earnings of $0.09 per share, significantly beating estimates, and …
Alaunos Therapeutics, Inc. reported its Q2 2026 financial results, showing no revenue and a reduced net loss of $988K, or $(0.41) diluted net loss per share. The company is advancing its preclinical metabolic programs, with lead oral candidate ALN1003 demonstrating positive results in weight …
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …
T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a beneficial ownership of 5,428,244 shares, or 4.9% of Quest Diagnostics Inc. common stock. The firm holds sole voting power over 5,321,387 shares and sole dispositive power over all 5,428,244 shares, while explicitly …
Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 9.99% in Co-Diagnostics (CODX), amounting to 559,706 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager. The filing indicates …
This article appears to be a stub or a placeholder, as the content provided is only "Document". It is intended to cover the stock options chain, quotes, and news for Co-diagnostics (CODX).
Co-Diagnostics Inc (CODX) stock closed at $1.39, down 6.71% on August 14th, with a market cap of $8.75 million. The company recently reported Q2 2026 revenue of $166,000, narrowed losses, and filed its flu and RSV assay with the FDA. Analysts currently rate CODX …
Assenagon Asset Management S.A. increased its stake in Quest Diagnostics Incorporated by 39.1% in the second quarter, acquiring 4,334 shares and bringing its total holdings to 15,405 shares valued at approximately $3.27 million. The medical research company reported strong Q2 earnings, exceeding estimates with …
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Market Access Progress Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …
This article provides a technical analysis of Quest Diagnostics Inc (DGX), detailing its current price momentum score, support and resistance levels, and indicator readings. It shows that DGX has a momentum score of 3.90, trading between resistance at $249.41 and support at $213.38. The …
Earnings Call Insights: Co-Diagnostics (CODX) Q2 2026 MANAGEMENT VIEW * Dwight Egan (Chairman, CEO & President) framed Q2 as “another important step in our transition from platform development toward commercialization,” emphasizing “advancing regulatory milestones, expanding our global commercial opportunities, enhancing our platform capabilities and …
Co-Diagnostics (CODX) reported significant losses and minimal revenue for Q2 2026, leading management to flag substantial doubt about its ability to continue as a going concern without additional capital. The company posted a net loss of $6.3 million for the quarter and $15.4 million …
Co-Diagnostics (CODX) shares surged by nearly 80% on Tuesday, extending a six-session rally that has seen the stock climb over 630%. This surge is attributed to the company's expanded efforts to develop a PCR test for the Bundibugyo strain of the Ebola virus, amidst …
Search by ticker symbol or company name and select a result to open its chart.